title: [Diabetic dyslipidaemia and the atherosclerosis].
abstract: The incidence and the public health importance of diabetes mellitus are growing continuously. Despite the improvement observed in recent years, the leading cause of morbidity and mortality of diabetics are cardiovascular diseases. The diagnosis of diabetes mellitus constitutes such a high risk as the known presence of vascular disease. Diabetic dyslipidaemia is characterised by high fasting and postprandial triglyceride levels, low HDL level, and slightly elevated LDL-cholesterol with domination of atherogenic small dense LDL. These are not independent components of the atherogenic dyslipidaemia, but are closely linked to each other. Beside the known harmful effects of low HDL and small dense LDL, recent findings confirmed the atherogenicity of the triglyceride-rich lipoproteins and their remnants. It has been shown that the key of this process is the overproduction and delayed clearance of triglyceride-rich lipoproteins in the liver. In this metabolism the lipoprotein lipase has a determining role; its function is accelerated by ApoA5 and attenuated by ApoC3. The null mutations of the ApoC3 results in a reduced risk of myocardial infarction, the loss-of-function mutation of ApoA5 was associated with a 60% elevation of triglyceride level and 2.2-times increased risk of myocardial infarction. In case of diabetes mellitus, insulin resistance, obesity, metabolic syndrome and chronic kidney disease the non-HDL-cholesterol is a better marker of the risk than the LDL-cholesterol. Its value can be calculated by subtraction of HDL-cholesterol from total cholesterol. Target values of non-HDL-cholesterol can be obtained by adding 0.8 mmol/L to the LDL-cholesterol targets (this means 3.3 mmol/L in high, and 2.6 mmol/L in very high risk patients). The drugs of first choice in the treatment of diabetic dyslipidaemia are statins. Nevertheless, it is known that even if statin therapy is optimal (treated to target), a considerable residual (lipid) risk remains. For its reduction treatment of low HDL-cholesterol and high triglyceride levels is obvious by the administration of fibrates. In addition to statin therapy, fenofibrate can be recommended.
authors.affiliation: II. Belgyógyászat-Kardiológia, Békés Megyei Pándy Kálmán Kórház Gyula, Semmelweis u. 1., 5700.
authors.forename: László
authors.initials: L
authors.lastname: Márk
authors.affiliation: II. Belgyógyászat-Kardiológia, Békés Megyei Pándy Kálmán Kórház Gyula, Semmelweis u. 1., 5700.
authors.forename: Győző
authors.initials: G
authors.lastname: Dani
mesh_terms: D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A / Q000378:metabolism; D001056:Apolipoproteins C / Q000378:metabolism; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000209:etiology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D048909:Diabetes Complications / Q000209:etiology / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000378:metabolism; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D011345:Fenofibrate / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008074:Lipoproteins / Q000097:blood; D024821:Metabolic Syndrome / Q000150:complications; D009765:Obesity / Q000150:complications; D011237:Predictive Value of Tests; D051436:Renal Insufficiency, Chronic / Q000150:complications; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
chemical_list: C437704:APOA5 protein, human; D000072040:Apolipoprotein A-V; D001054:Apolipoproteins A; D001056:Apolipoproteins C; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D014280:Triglycerides; C030087:lipoprotein triglyceride; D008071:Lipoprotein Lipase; D011345:Fenofibrate
keywords: cardiovascular risk; cardiovascularis kockázat; diabetes mellitus; diabeteses dyslipidaemia; diabetic dyslipidaemia; fibrát; statin; statin fibrate